ASCO GU 2022 – Janssen Highlights Niraparib Combo Data

Dr. Eleni Efstathiou, MD, PhD, Section Chief of Genitourinary Medical Oncology at Houston Methodist Oncology Partners and​ an​ investigator on the Phase 3 MAGNITUDE study​ discusses new data showing that first-line use of niraparib​ in ​combination with abiraterone acetate (Zytiga) plus prednisone, significantly improves progression-free survival in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.​ These data were presented at the American Society of Clinical Oncology’s Genitourinary​ Cancers Symposium 2022.

Eleni Efstathiou, MD, PhD, Genitourinary Medical Oncology, Section Chief of Genitourinary Medical Oncology at Houston Methodist Oncology Partners

Dr. Efstathiou focuses on tissue-based translational research in prostate cancer and has established two labs dedicated to this work—the Stanford Alexander tissue and derivatives laboratory and the Eckstein laboratory that centers on the interaction with clinic and patient and collection of tissue and other research samples. Her work has included exploring the impact of novel therapeutic agents on the tumor microenvironment and associating with pretreatment molecular characteristics that have significantly impacted research practices and promoted precision therapy pursuit.  Dr. Efstathiou has received both the Young Investigator Award and the Career Development Award from the Prostate Cancer Foundation. She has been published in numerous peer-reviewed medical journals including Lancet Oncology, European Eurology and many others.  Dr. Efsthathiou is dedicated to prostate cancer research and is considered an international expert in spearheading and forging therapy development strategies in prostate cancer. She’s currently continuing her research to help classify the disease and target appropriately in the search for a cure for prostate cancer.